TABLE 2.
OR (95% CI) data from the total group for the death rate and safety index according to treatment group.
| OR (95% CrI)-column vs. row | |||||
|---|---|---|---|---|---|
| Death rate group | |||||
| D | DF | F | DS | S | |
| D | # | # | 0.35 (−2.34, 3.45) | 1.15 (−1.84, 4.56) | |
| DF | 0.77 (−2.25, 3.89) | 2.35 (−1.31, 7.44) | 1.15 (−2.57, 5.27) | 1.96 (−2, 6.27) | |
| F | 0.9 (−1.63, 3.61) | 0.11 (−3.22, 3.62) | 1.27 (−1.96, 4.96) | 2.07 (−1.38, 6.01) | |
| DS | # | # | # | 0.79 (−1.88, 3.49) | |
| S | # | # | # | # | |
| Safety index group | |||||
| D | DF | F | DS | S | |
| D | # | # | 2.53 (−1.35, 7.39) | 0.89 (−2.6, 4.79) | |
| DF | 0.37 (−4.17, 4.84) | # | 2.92 (−2.5, 9.09) | 1.26 (−3.97, 6.76) | |
| F | 0.47 (−2.97, 3.84) | 0.02 (−4.44, 4.99) | 3 (−1.55, 8.46) | 1.35 (−2.9, 5.95) | |
| DS | # | # | # | # | |
| S | # | # | # | 1.66 (−1.71, 5.44) | |
All network meta-analysis comparisons are represented in table but only Digoxin as baseline in forest plot (Figure 3). As shown in Table 2, no significant difference existed in death rate group, but S appeared to be more safe though less efficacious. After considering both effectiveness and safety in the safety index group, no significant differences were observed in all five regimens.
OR, odds ratio; CrI, credible interval; D, digoxin monotherapy; DF, digoxin and flecainide combination therapy; DS, digoxin and sotalol combination therapy; F, flecainide monotherapy; S, sotalol monotherapy; SVT, supraventricular tachycardia; AF, atrial flutter.